|
Fig. 5 Treatment with the myosin 2 inhibitor blebbistatin decreases actin recruitment in the YSL and slows the rate of EVL epiboly.(A,B) Bright-field image of an untreated embryo at bud stage (A) and a (±)-blebbistatin-treated embryo (B). (C) Quantification of epiboly defects resulting from blebbistatin treatments. Shown are the percentages of embryos displaying delayed epiboly (80-95% epiboly) when untreated embryos had reached the 100% epiboly stage. Numbers are based on two independent experiments. Abbreviations: co, untreated control; (+)Blb, (+)-blebbistatin treatment; (±)Blb, (±)-blebbistatin treatment. (D,E) Phalloidin (F-actin) staining of a control embryo at 75% epiboly and a (±)-blebbistatin-treated embryo. (F,G) Phalloidin staining of an untreated embryo at 90% epiboly (F) and (±)-blebbistatin-treated embryo (G), both injected with a morpholino against half baked/E-cadherin. Scale bars: in B, 100 μm for A,B; in E, 50 μm for D,E; in G, 25 μm for F,G.